Vascular restenosis, an overreaction of biological response to injury, is initialized by thrombosis and inflammation. This response is characterized by increased smooth muscle cell migration and proliferation. Available pharmacological treatments include anticoagulants, antiplatelet agents, immunosuppressants, and antiproliferation agents. Protein kinase C (PKC), a large family of serine/threonine kinases, has been shown to participate in various pathological stages of restenosis. Consequently, PKC inhibitors are expected to exert a wide range of pharmacological activities therapeutically beneficial for restenosis. In this review, the roles of PKC isozymes in platelets, leukocytes, endothelial cells, and smooth muscle cells are discussed, with emphasis given to smooth muscle cells. We will describe cellular and animal studies assessing prevention of restenosis with PKC inhibitors, particularly targeting -α, -β, -δ, and -ζ isozymes. The delivery strategy, efficacy, and safety of such PKC regulators will also be discussed.
Mitra AK, Agrawal DK In stent restenosis: bane of the stent era. J Clin Pathol. 2006;59(3):232-239.
4.
Kraitzer A., Kloog Y., Zilberman M.Approaches for prevention of restenosis. J Biomed Mater Res B Appl Biomater. 2008;85(2): 583-603.
5.
Zargham R.Preventing restenosis after angioplasty: a multistage approach. Clin Sci (Lond). 2008;114(4):257-264.
6.
Meier M., King GLProtein kinase C activation and its pharmacological inhibition in vascular disease. Vasc Med. 2000;5(3):173-185.
7.
Churchill E., Budas G., Vallentin A., Koyanagi T., Mochly-Rosen D.PKC isozymes in chronic cardiac disease: possible therapeutic targets?Annu Rev Pharmacol Toxicol. 2008;48:569-599.
8.
Grange JJ, Baca-Regen LM, Nollendorfs AJ, Persidsky Y., Sudan DL, Baxter BTProtein kinase C isoforms in human aortic smooth muscle cells. J Vasc Surg. 1998;27(5):919-926.
9.
Mattila P., Majuri ML, Tiisala S., Renkonen R.Expression of six protein kinase C isotypes in endothelial cells. Life Sci. 1994; 55(16):1253-1260.
10.
Magid R., Davies PFEndothelial protein kinase C isoform identity and differential activity of PKCzeta in an athero-susceptible region of porcine aorta. Circ Res. 2005;97(5):443-449.
11.
Duan C.The chemotactic and mitogenic responses of vascular smooth muscle cells to insulin-like growth factor-I require the activation of ERK1/2. Mol Cell Endocrinol. 2003;206(1-2):75-83.
12.
Yamaguchi H. , Igarashi M., Hirata A., et al. Altered PDGF-BBinduced p38 MAP kinase activation in diabetic vascular smooth muscle cells: roles of protein kinase C-delta. Arterioscler Thromb Vasc Biol. 2004 ;24(11):2095-2101.
13.
Ginnan R., Singer HAPKC-delta-dependent pathways contribute to PDGF-stimulated ERK1/2 activation in vascular smooth muscle. Am J Physiol Cell Physiol. 2005;288(6):C1193-C1201.
Lewis JM, Cheresh DA, Schwartz MAProtein kinase C regulates alpha v beta 5-dependent cytoskeletal associations and focal adhesion kinase phosphorylation. J Cell Biol. 1996;134(5):1323-1332.
16.
Capellini VK , Celotto AC, Baldo CF, et al. Diabetes and vascular disease: basic concepts of nitric oxide physiology, endothelial dysfunction, oxidative stress and therapeutic possibilities. Curr Vasc Pharmacol.2010;8(4):526-544.
17.
Kappert K., Furundzija V., Fritzsche J., et al. Integrin cleavage regulates bidirectional signalling in vascular smooth muscle cells. Thromb Haemost.2010;103(3):556-563.
18.
Leduc I., Meloche S. Angiotensin II stimulates tyrosine phosphorylation of the focal adhesion-associated protein paxillin in aortic smooth muscle cells. J Biol Chem. 1995;270(9):4401-4404.
19.
Li C., Wernig F., Leitges M., Hu Y., Xu Q.Mechanical stress-activated PKCdelta regulates smooth muscle cell migration . FASEB J.2003;17(14):2106-2108.
20.
Carter AJ, Laird JR, Farb A., Kufs W., Wortham DC, Virmani R.Morphologic characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis model. J Am Coll Cardiol. 1994;24(5):1398-1405.
21.
Greif M., Pohl T., Oversohl N., Reithmann C., Steinbeck G., Becker A.Acute stent thrombosis in a sirolimus eluting stent after wasp sting causing acute myocardial infarction: a case report. Cases J. 2009;2:7800.
22.
Harper MT, Poole AWDiverse functions of protein kinase C isoforms in platelet activation and thrombus formation. J Thromb Haemost.2010 ;8(3):454-462.
23.
Gilio K., Harper MT, Cosemans JM, et al. Functional divergence of platelet PKC isoforms in thrombus formation on collagen. J Biol Chem..2010;285(30):23410-23419.
24.
Konopatskaya O., Gilio K., Harper MT, et al. PKCalpha regulates platelet granule secretion and thrombus formation in mice. J Clin Invest.2009;119(2):399-407.
25.
Yoshioka A. , Shirakawa R., Nishioka H., et al. Identification of protein kinase Calpha as an essential, but not sufficient, cytosolic factor for Ca2+-induced alpha- and dense-core granule secretion in platelets. J Biol Chem . 2001;276(42):39379-39385.
26.
Tabuchi A., Yoshioka A., Higashi T., et al. Direct demonstration of involvement of protein kinase Calpha in the Ca2+-induced platelet aggregation. J Biol Chem. 2003;278(29):26374-26379.
27.
Pula G., Crosby D., Baker J., Poole AWFunctional interaction of protein kinase Calpha with the tyrosine kinases Syk and Src in human platelets. J Biol Chem. 2005;280(8):7194-7205.
28.
Crosby D., Poole AWPhysical and functional interaction between protein kinase C delta and Fyn tyrosine kinase in human platelets. J Biol Chem. 2003;278(27):24533-24541.
29.
Pula G., Schuh K., Nakayama K., Nakayama KI, Walter U., Poole AWPKCdelta regulates collagen-induced platelet aggregation through inhibition of VASP-mediated filopodia formation. Blood. 2006;108(13):4035-4044.
30.
Hall KJ, Harper MT, Gilio K., Cosemans JM, Heemskerk JW, Poole AWGenetic analysis of the role of protein kinase Ctheta in platelet function and thrombus formation. PLoS One. 2008; 3(9):e3277.
31.
Chari R., Getz T., Nagy B. Jr, et al. Protein kinase C[delta] differentially regulates platelet functional responses. Arterioscler Thromb Vasc Biol.2009;29(5):699-705.
32.
Nagy B. Jr , Bhavaraju K., Getz T., Bynagari YS, Kim S., Kunapuli SPImpaired activation of platelets lacking protein kinase C-theta isoform. Blood.2009;113(11):2557-2567.
33.
Cohen S., Braiman A., Shubinsky G., Ohayon A., Altman A., Isakov N.PKCtheta is required for hemostasis and positive regulation of thrombin-induced platelet aggregation and alpha-granule secretion. Biochem Biophys Res Commun.2009;385(1):22-27.
34.
Abdala-Valencia H., Cook-Mills JMVCAM-1 signals activate endothelial cell protein kinase C-alpha via oxidation. J Immunol. 2006 ;177(9):6379-6387.
35.
Kouroedov A. , Eto M., Joch H., Volpe M., Lüscher TF, Cosentino F.Selective inhibition of protein kinase Cbeta2 prevents acute effects of high glucose on vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 2004;110(1):91-96.
36.
Javaid K., Rahman A., Anwar KN, Frey RS, Minshall RD, Malik ABTumor necrosis factor-alpha induces early-onset endothelial adhesivity by protein kinase Czeta-dependent activation of intercellular adhesion molecule-1 . Circ Res. 2003;92(10): 1089-1097.
37.
Ni CW, Wang DL, Lien SC, Cheng JJ, Chao YJ, Hsieh HJActivation of PKC-epsilon and ERK1/2 participates in shear-induced endothelial MCP-1 expression that is repressed by nitric oxide. J Cell Physiol. 2003;195(3):428-434.
38.
Laudanna C., Mochly-Rosen D., Liron T., Constantin G., Butcher ECEvidence of zeta protein kinase C involvement in polymorphonuclear neutrophil integrin-dependent adhesion and chemotaxis. J Biol Chem. 1998;273(46):30306-30315.
39.
Okazaki J., Mawatari K., Liu B., Kent KCThe effect of protein kinase C and its alpha subtype on human vascular smooth muscle cell proliferation, migration and fibronectin production. Surgery. 2000;128(2):192-197.
40.
Campbell M., Trimble ERModification of PI3K- and MAPKdependent chemotaxis in aortic vascular smooth muscle cells by protein kinase CbetaII. Circ Res. 2005;96(2):197-206.
41.
Ohtsu H., Mifune M., Frank GD, et al. Signal-crosstalk between Rho/ROCK and c-Jun NH2-terminal kinase mediates migration of vascular smooth muscle cells stimulated by angiotensin II. Arterioscler Thromb Vasc Biol. 2005;25(9):1831-1836.
42.
Kamiya K., Ryer E., Sakakibara K., Zohlman A., Kent KC, Liu B.Protein kinase C delta activated adhesion regulates vascular smooth muscle cell migration. J Surg Res.2007;141(1):91-96.
43.
Liu B., Ryer EJ, Kundi R., et al. Protein kinase C-delta regulates migration and proliferation of vascular smooth muscle cells through the extracellular signal-regulated kinase 1/2. J Vasc Surg. 2007;45(1):160-168.
44.
Ding Q., Chai H., Mahmood N., Zhou W.Resistin promotes vascular smooth muscle cell migration via matrix metalloproteinases. S. 2010;158(2):299.
45.
Leszczynski D., Joenväärä S., Foegh MLProtein kinase C-alpha regulates proliferation but not apoptosis in rat coronary vascular smooth muscle cells. Life Sci. 1996;58:599-606.
46.
Marilley D. , Mosieniak G., Boscoboinik D., Azzi A.Correlation between human vascular smooth muscle cell proliferation and protein kinase C alpha-expression: effect of d-alpha-tocopherol. Biochem Mol Biol Int. 1996;40(4):699-707.
47.
Sasaguri T. , Kosaka C., Hirata M., et al. Protein kinase C-mediated inhibition of vascular smooth muscle cell proliferation: the isoforms that may mediate G1/S inhibition. Exp Cell Res. 1993; 208(1):311-20.
48.
Wang S., Desai D., Wright G., Niles RM, Wright GLEffects of protein kinase C alpha overexpression on A7r5 smooth muscle cell proliferation and differentiation. Exp Cell Res. 1997;236(1):117-126.
49.
Yamamoto M. , Acevedo-Duncan M., Chalfant CE, Patel NA, Watson JE, Cooper DRAcute glucose-induced downregulation of PKC-betaII accelerates cultured VSMC proliferation. Am J Physiol Cell Physiol. 2000;279(3):C587-C595.
50.
Nakamura J. , Kasuya Y., Hamada Y., et al. Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity . Diabetologia. 2001; 44(4):480-487.
51.
Yasuda Y., Nakamura J., Hamada Y., et al. Role of PKC and TGFbeta receptor in glucose-induced proliferation of smooth muscle cells. Biochem Biophys Res Commun. 2001;281(1):71-77.
52.
Heo KS, Kim DU, Kim L., et al. Activation of PKCbeta(II) and PKCtheta is essential for LDL-induced cell proliferation of human aortic smooth muscle cells via Gi-mediated Erk1/2 activation and Egr-1 upregulation. Biochem Biophys Res Commun . 2008;368(1):126-131.
53.
Ling S., Little PJ, Williams MR, et al. High glucose abolishes the antiproliferative effect of 17beta-estradiol in human vascular smooth muscle cells. Am J Physiol Endocrinol Metab. 2002; 282(4):E746-E751.
54.
Andrassy M. , Belov D., Harja E., et al. Central role of PKCbeta in neointimal expansion triggered by acute arterial injury. Circ Res. 2005;96(4):476-483.
55.
Skaletz-Rorowski A., Eschert H., Leng J., et al. PKC delta-induced activation of MAPK pathway is required for bFGF-stimulated proliferation of coronary smooth muscle cells. Cardiovasc Res. 2005;67(1):142-150.
56.
Leitges M., Mayr M., Braun U., et al. Exacerbated vein graft arteriosclerosis in protein kinase Cdelta-null mice. J Clin Invest. 2001; 108(10):1505-1512.
57.
Zhao Y., Liu J., Li L., Liu L., Wu L.Role of Ras/PKCzeta/MEK/ ERK1/2 signaling pathway in angiotensin II-induced vascular smooth muscle cell proliferation. Regul Pept. 2005;128(1): 43-50.
58.
Parmentier JH, Zhang C., Estes A., Schaefer S., Malik KUEssential role of PKC-zeta in normal and angiotensin II-accelerated neointimal growth after vascular injury. Am J Physiol Heart Circ Physiol. 2006;291(4):H1602-H1613.
59.
Hussain S., Assender JW, Bond M., Wong LF, Murphy D., Newby ACActivation of protein kinase Czeta is essential for cytokine-induced metalloproteinase-1, -3, and -9 secretion from rabbit smooth muscle cells and inhibits proliferation . J Biol Chem. 2002;277(30):27345-27352.
60.
Babapulle MN , Eisenberg MJCoated stents for the prevention of restenosis: partI. Circulation. 2002;106(21):2734-2740.
61.
Fabian MA, Biggs WH 3rd, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005;23(3):329-336.
62.
Yang CM, Chien CS, Hsiao LD, et al. Mitogenic effect of oxidized low-density lipoprotein on vascular smooth muscle cells mediated by activation of Ras/Raf/MEK/MAPK pathway. Br J Pharmacol. 2001;132(7):1531-1541.
63.
Mamputu JC, Levesque L., Renier G.Proliferative effect of lipoprotein lipase on human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2000 ;20(10):2212-2219.
64.
Pang X., Sun NLCalcineurin-NFAT signaling is involved in phenylephrine-induced vascular smooth muscle cell proliferation. Acta Pharmacol Sin.2009;30(5):537-544.
65.
Ferro T., Neumann P., Gertzberg N., Clements R., Johnson A.Protein kinase C-alpha mediates endothelial barrier dysfunction induced by TNF-alpha. Am J Physiol Lung Cell Mol Physiol. 2000;278(6):L1107-L1117.
66.
Stebbins EG , Mochly-Rosen D."Binding specificity for RACK1 resides in the V5 region of beta II protein kinase C.’’J Biol Chem. 2001;276(32):29644-29650.
67.
Cho HM, Choi SH, Hwang KC, et al. The Src/PLC/PKC/MEK/ ERK signaling pathway is involved in aortic smooth muscle cell proliferation induced by glycated LDL. Mol Cells. 2005;19(1): 60-66.
68.
Watanabe T., Pakala R., Katagiri T., Benedict CRSynergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. J Hypertens. 2001;19(12):2191-2196.
Watanabe T., Pakala R., Katagiri T., Benedict CRSynergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation. 2001; 104(1):16-18.
71.
Yano K., Bauchat JR, Liimatta MB, Clemmons DR, Duan C.Down-regulation of protein kinase C inhibits insulin-like growth factor I-induced vascular smooth muscle cell proliferation, migration, and gene expression . Endocrinology. 1999;140(10): 4622-4632.
72.
Cogo A., Napolitano G., Michoud MC, Barbon DR, Ward M., Martin JGEffects of hypoxia on rat airway smooth muscle cell proliferation. J Appl Physiol. 2003;94(4):1403-1409.
73.
Chen L., Hahn H., Wu G., et al. Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC. Proc Natl Acad Sci U S A. 2001;98(20):11114-11119.
74.
Bates E., Bode C., Costa M., et al. Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction . Circulation. 2008; 117(7):886-896.
75.
Soltoff SPRottlerin: an inappropriate and ineffective inhibitor of PKCdelta. Trends Pharmacol Sci. 2007;28(9):453-458.
76.
Harrison DG , Sayegh H., Ohara Y., et al. Regulation of expression of the endothelial cell nitric oxide synthase. Clin Exp Pharmacol Physiol. 1996;23:251-255.
77.
Rosales OR, Isales CM, Bhargava J.Overexpression of protein kinase C alpha and beta1 has distinct effects on bovine aortic endothelial cell growth. Cell Signal. 1998;10(8):589-597.
78.
Xu H., Goettsch C., Xia N., et al. Differential roles of PKCalpha and PKCepsilon in controlling the gene expression of Nox4 in human endothelial cells. Free Radic Biol Med. 2008;44(8):1656-1667.
79.
Tanaka M., Terry RD, Mokhtari GK, et al. Suppression of graft coronary artery disease by a brief treatment with a selective epsilonPKC activator and a deltaPKC inhibitor in murine cardiac allografts. Circulation. 2004;110(11suppl1):11194-11199.
80.
Tanaka M., Gunawan F., Terry RD, et al. Inhibition of heart transplant injury and graft coronary artery disease after prolonged organ ischemia by selective protein kinase C regulators . J Thorac Cardiovasc Surg. 2005;129(5):1160-1167.
81.
Whitson EL, Bugni TS, Chockalingam PS, et al. Spheciosterol sulfates, PKCzeta inhibitors from a philippine sponge Spheciospongia sp. J Nat Prod. 2008 ;71(7):1213-1217.
82.
Kastrati A. , Schuhlen H., Hausleiter J., et al. Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial. Circulation. 1997;96(2):462-467.
83.
Ellis SG, Effron MB, Gold HK, et al. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation. 1999 ;100(8):799-806.
84.
Lee CW, Chae JK, Lim HY, et al. Prospective randomized trial of corticosteroids for the prevention of restenosis after intracoronary stent implantation. Am Heart J. 1999;138(1pt1):60-63.
85.
Welt FG, Rogers C.Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol. 2002;22(11):1769-1776.
86.
Rodriguez AE , Fernandez-Pereira C.Systemic immunosuppressive therapy with oral Sirolimus after bare metal stent implantation: the missing alternative in the prevention of coronary restenosis after percutaneous coronary interventions. Recent Pat Cardiovasc Drug Discov. 2008;3(3):201-208.
87.
Kuchulakanti P., Waksman R.Therapeutic potential of oral antiproliferative agents in the prevention of coronary restenosis. Drugs. 2004;64(21):2379-2388.
88.
Inagaki K., Koyanagi T., Berry NC, Sun L., Mochly-Rosen D.Pharmacological inhibition of epsilon-protein kinase C attenuates cardiac fibrosis and dysfunction in hypertension-induced heart failure. Hypertension. 2008;51(6):1565-1569.
89.
Babapulle MN , Eisenberg MJCoated stents for the prevention of restenosis: PartI. Circulation. 2002;106(21):2734-2740.
90.
Babapulle MN , Eisenberg MJ. Coated stents for the prevention of restenosis: Part II. Circulation. 2002;106(22):2859-2866.
